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Background: The mutation and amplification of oncogenic genes
are associated with carcinogenesis and tumor growth. The purpose
of this study was to clarify the role of the epidermal growth factor
receptor (EGFR), K-ras, MET, and hepatocyte growth factor (HGF)
status in lung adenocarcinoma.
Methods: Tumor specimens were collected from 183 patients who
underwent a complete resection for adenocarcinoma of the lung
from 2003 to 2007 in our department. The genetic status of the
EGFR and K-ras genes were investigated by polymerase chain
reaction (PCR)-based analyses. Immunohistochemistry and real time
PCR assays were used to evaluate the MET gene regarding to
tyrosine phosphorylation and amplification, respectively. HGF sta-
tus was evaluated by immunohistochemistry.
Results: The mutations of EGFR and K-ras were detected in 64
(35%) and 17 patients (9%), respectively. The tyrosine 1234/1235
phosphorylation of MET (p-MET 1234/1235) and MET amplifica-
tion was identified in 12 (7%) and 8 (4%) specimens, respectively.
Positive expression of HGF was identified in 104 specimens (57%).
An EGFR mutation was found significantly more frequently in
females and in tumors with wild type of K-ras and without MET
amplification. A p-MET 1234/1235 was found significantly more
frequently in the tumors with a positive expression of HGF. A
multivariate survival analysis demonstrated that the wild type of
K-ras, negative p-MET 1234/1235, and positive HGF expression
were independently associated with an increased risk of poor sur-
vival.
Conclusions: The occurrence of MET amplification and EGFR/
K-ras mutations might be mutually exclusive suggesting several
distinct mechanisms in the development of lung adenocarcinoma.
The wild type of K-ras, negative p-MET 1234/1235, and positive
expression of HGF may be a useful marker for predicting poor
prognosis of patients who underwent surgical resection of lung
adenocarcinoma.
Key Words: EGFR, K-ras, MET, HGF, Lung cancer,
Adenocarcinoma.
(J Thorac Oncol. 2010;5: 591–596)
Lung cancer is the leading cause of cancer-related deaths inJapan, and it kills more than 60,000 people per year.1 The
incidence of adenocarcinoma, one of the major histologic
subtypes of non-small cell cancer (NSCLC), has been re-
ported to be increasing recently.2 It is a malignancy with a
poor prognosis. Even in patients who achieve complete sur-
gical resection, the 5-year survival is only around 50%.3
Therefore, it is important to evaluate the malignant potential
of tumor cells for a more precise evaluation of the prognosis
of patients.
Somatically acquired mutations in the epidermal
growth factor receptor (EGFR) gene in NSCLC are associ-
ated with a significant clinical response to EGFR-tyrosine
kinase inhibitors (TKI).4–7 However, most of the patients
with this type of sensitive mutations in their tumor show
acquired resistance during the TKI treatment.8–11 The numer-
ous findings for the resistant-related molecules lead to accu-
mulation of the basic research. The p-MET initiates distinct
signal transduction cascades involving such signaling mole-
cules as Erk, Akt, and Stat3.12 Deregulation of hepatocyte
growth factor (HGF)-MET signaling may result in carcino-
genesis in several solid tumors.13 However, to our knowl-
edge, few studies using cancer specimen have been con-
ducted from a translational viewpoint. MET was identified as
the receptor for HGF, and amplification of MET has been
reported to be associated with 20% of lung adenocarcinoma
with acquired resistance to EGFR-TKI.14,15 Overexpression
of HGF also may cause an acquired resistance to EGFR-
TKI.16 On the other hand, the K-ras mutation is associated
with primary resistance to EGFR-TKI.17
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This is the first comprehensive molecular analysis of
the EGFR, K-ras, MET, and HGF status with regard to the
prognosis of patients with lung adenocarcinoma to elucidate
their clinical significance.
PATIENTS AND METHODS
Patients and Clinical Features
Tumor samples were obtained from 296 patients with
primary lung adenocarcinoma who had undergone a surgical
resection between 2003 and 2007 in our department. Nine of
these patients were stage IV and 25 underwent an incomplete
resection. The tumor samples from 79 patients were too small
to extract sufficient DNA for all of the analyses include the
determination of the EGFR, K-ras, and MET amplification
and to evaluate immunohistochemical (IHC) staining for
p-MET 1234/1235 and HGF status. As a result, 113 patients
were excluded from further analysis. Therefore, 183 tumor
specimens were evaluated.
As genetic variables of lung adenocarcinoma, the
EGFR mutations, K-ras mutation, p-MET 1234/1235, ampli-
fication of MET, and HGF expression were examined, and
the correlation of these genetic factors with the clinicopath-
ological variables were analyzed. The institutional review
board’s approved informed consent for the use of the tumor
specimens was obtained either from all the patients or from
the patient’s legal guardians. The patients were followed-up
every month within the first postoperative year and at approx-
imately at 2 to 4 months intervals thereafter. The evaluations
included a physical examination, chest roentgenography, an
analysis of blood chemistry, and measurements of tumor
markers. Chest and abdominal computed tomography, brain
magnetic resonance imaging, and a bone scintiscan were
performed every 6 months for 3 years after surgery. Addi-
tional examinations were performed if any symptoms or signs
of recurrence were detected. Twenty-seven (14.8%) patients
had received adjuvant chemotherapy as follows: 18, carbo-
platin plus paxclitaxel; 7, carboplatin plus gemcitabine; and
2, tegafur-uracil. Twelve patients received 250 mg/d of ge-
fitinib for their recurrence. The median follow-up period was
34. 2 months, ranged from 1.0 to 70.0 months.
Detection of EGFR Mutations
The genomic DNA was extracted from each tumor. The
EGFR mutations were examined by previously described
methods, as reported previously.19 Briefly, the exon 19 dele-
tion of EGFR was detected by a simple screening method,
which was the detection of shorter band than 147 base pair
(bp) on agarose gel electrophoresis of the PCR product,
derived from wild-type allele. The exon 21 L858R point
mutation was detected by mutant-allele specific amplifica-
tion. The 3 ends of 22-bp oligonucleotides used as PCR
primers corresponded to G for T of EGFR codon 858. That is,
the sense-primer sequence for wild type was 5-TCAAGAT-
CACAGATTTTGGGCT, and that for L858R mutation
was 5-TCAAGATCACAGATTTTGGGCG. The antisense
primer for both wild type and mutant type was 5-CATC-
CTCCCCTGCATGTGTTAAAC. The PCR products were
run on electrophoresis on a 2% agarose gel.
Detection of K-ras Mutations
A designed-restriction fragment length polymorphism
method was used to detect K-ras codon 12 mutations.19
Briefly, a sense-mismatched primer was used to introduce a
new restriction site into the PCR product derived from the
wild-type allele. The newly introduced restriction site was
BstNI for screening of codon 12. The wild-type alleles were
digested and they yielded a smaller product (77 bp) than the
mutant forms (97 bp), which were digestive resistant.
IHC Staining for Phosphorylation of MET
The 3-m thick sections cut from paraffin-embedded
specimens were prepared on glass slides for the phosphory-
lation of MET IHC staining. All of the specimens were
stained with hematoxylin and eosin for the histopathologic
diagnosis. The sections were placed in 0.01 mol/L citrate
buffer (pH 6.0) and autoclaved at 121°C for 10 minutes. They
were treated with 3% H2O2 for 5 minutes to block the
endogenous peroxidase activity. The primary antibodies used
were a monoclonal Ab against p-MET 1234/1235 (#3077,
Cell Signaling Technologies, Danvers, MA), diluted 1:100 in
phosphate buffered-saline, and incubated for 18 hours at 4°C.
Thereafter, IHC staining was performed by the labeled poly-
mer method (Histofine Simple Stain MAX-PO kit, Nichirei,
Tokyo, Japan) according to the manufacturer’s instructions.
The positive and the negative controls were processed by the
breast cancer specimen harboring phosphorylation of MET
and the exclusion of the primary antibody, respectively. The
stained specimens were then categorized into 8 degrees ac-
cording to the IHC Allred score.20 Initially, 6 degrees of the
proportional score for the positive staining cells were as-
signed according to the frequency of positive tumor cells (0,
none; 1,1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3;
and 5, 2/3). Thereafter, 4 degrees for the intensity score
were assigned according to the intensity of the staining (0,
none; 1, weak; 2, intermediate; and 3, strong). The propor-
tional score and the intensity score were then added to each
other to obtain a total score, which ranged from 0 to 8.
According to the total IHC Allred score, the MET phosphory-
lation of the tumor was categorized as a negative expression
when the score was 0 to 2 and a positive expression when the
score was 3 to 8. The slides were independently examined by
two of the investigators (T. O. and H. U.) who were blinded
to the clinicopathological data. When a discrepancy was
found between the two investigators, a consensus was
reached via their simultaneous examination using a double-
headed microscope.
Detection of MET Amplification
The MET gene copies were examined by previously
described methods.15 The MET gene copy number was ana-
lyzed by a quantitative real-time PCR method, performed on
a StepOnePlus Real-Time PCR System (Applied Biosystems,
Foster City, CA) using a Fast SYBR Green Master Mix
(Applied Biosystems). Each DNA sample of tumors was
quantified by comparing the target locus to beta actin as an
internal control. The quantification was based on the standard
curves from a serial dilution of the human normal genomic
DNA. PCR was performed for each primer set in triplicate,
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and the mean value was calculated.15 Amplification was
defined as a copy number more than 1.31 copies, which was
calculated by the mean of the MET gene copy number
measured plus two times of standard deviation in this study.21
IHC Staining for HGF
The antibody used was a rabbit polyclonal anti-HGF
Ab (sc-7949, Santa Cruz Biotechnology, Santa Cruz, CA)
diluted 1:100 in phosphate buffered-saline, and incubated for
18 hours at 4°C.15 The positive and the negative controls were
processed by the normal gallbladder harboring over expres-
sion of HGF and the exclusion of the primary antibody,
respectively. The proportion and intensity of stained cells
were categorized into 8 degrees according to the IHC Allred
score, and the results were categorized to positive and nega-
tive in the same manner as that for p-MET 1234/1235.
Statistical Analysis
Statistical associations were determined by the 2 test.
The Cox proportional hazards model was applied to the
multivariate survival analysis. The statistical difference was
considered to be significant if the p value was less than 0.05.
The data were analyzed with the use of Abacus Concepts,
Survival Tools for Stat View (Abacus Concepts, Inc., CA).
RESULTS
Mutation of the EGFR and K-ras
All of the patients were Japanese. The subjects included
102 men and 81 women in this series, with a mean age of 68.5
years (range 23–88). The tumor stage was classified accord-
ing to the Revisions in the International System for Staging
Lung Cancer.18 According to the pathologic stage, 113 pa-
tients were at stage IA, 35 at IB, 7 at IIA, 10 at IIB, 15 at IIIA,
and 3 at IIIB. EGFR mutations were detected in 64 of 183
patients (35%). There were 41 of exon 21 L858R point
mutation and 23 of exon 19 deletion mutation. The EGFR
mutations were found significantly more frequently in fe-
males than males (p  0.001). EGFR mutations, K-ras
mutations, and MET amplification were all mutually exclu-
sive. There were no patients with both EGFR and K-ras
mutations, or EGFR mutations and MET amplification. No
significant association of EGFR mutation was observed with
age, pathologic stage, T status, N status, p-MET 1234/1235,
or HGF expression. K-ras mutation was identified in 17
patients (9%). No significant association of K-ras mutation
was identified with regard to various clinical factors,
p-MET1234/1235, amplification of MET, and HGF expres-
sion (Table 1).
TABLE 1. Relationships Between Molecular Parameters and Clinicopathological Characteristics
Variables Category
No. of
Patients
(n  183)
EGFR K-ras p-MET
MET
Amplification
HGF
Expression
Mut (%) 
64 (35)
Wt 
119
Mut (%) 
17 (9)
Wt 
166
P (%) 
12 (7)
N 
171
P (%) 
8 (4)
N 
175
P (%) 
104 (57)
N 
79
Gender Male 102 23 (23) 79 12 (12) 90 8 (8) 94 6 (6) 96 54 (53) 48
Female 81 41 (51) 40a 5 (6) 76 4 (5) 77 2 (2) 79 50 (62) 31
Age (y) 69 80 30 (38) 50 6 (8) 74 8 (10) 72 5 (6) 75 43 (54) 37
69 103 34 (33) 69 11 (11) 92 4 (4) 99 3 (3) 100 61 (59) 42
Pathologic stage I 148 54 (36) 94 12 (8) 136 9 (6) 139 5 (3) 143 80 (54) 68
II–III 35 10 (29) 25 5 (14) 30 3 (9) 32 3 (9) 32 24 (69) 11
T status T1 128 50 (39) 78 10 (8) 118 8 (6) 120 6 (5) 122 71 (55) 57
T2–4 55 14 (25) 41 7 (13) 48 4 (7) 51 2 (4) 53 33 (60) 22
N status Negative 152 54 (36) 98 13 (9) 139 10 (7) 142 5 (3) 147 83 (55) 69
Positive 31 10 (32) 21 4 (13) 27 2 (6) 29 3 (10) 28 21 (68) 10
EGFR mutation Mutated 64 — — 0 (0) 64 3 (5) 61 0 (0) 64 37 (58) 27
Wild 119 — — 17 (14) 102b 9 (8) 110 8 (7) 111c 67 (56) 52
K-ras mutation Mutated 17 0 (0) 17 — — 2 (12) 15 0 (0) 17 13 (76) 4
Wild 166 64 (39) 102c — — 10 (6) 156 8 (5) 158 91 (55) 75
p-MET Positive 12 3 (25) 9 2 (17) 10 — — 0 (0) 12 11 (92) 1
Negative 171 61 (36) 110 15 (9) 156 — — 8 (5) 163 93 (54) 78d
MET amplification Positive 8 0 (0) 8 0 (0) 8 0 (0) 8 — — 3 (38) 5
Negative 175 64 (37) 111d 17 (10) 158 12 (7) 163 — — 101 (58) 74
HGF expression Positive 104 37 (36) 67 13 (13) 91 11 (11) 93 3 (3) 101 — —
Negative 79 27 (34) 52 4 (5) 75 1 (1) 78d 5 (6) 74 — —
a, b, c, d Means statistically significant.
a p  0.001.
b p  0.002.
c p  0.034.
d p  0.012.
Mut, mutation; Wt, wild type; P, positive; N, negative; EGFR, epidermal growth factor receptor; p-MET, tyrosine 1234/1235 phosphorylation of MET; HGF, hepatocyte growth
factor.
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IHC Analysis of p-MET 1234/1235
Staining of p-MET 1234/1235 was mainly found in the
membranes and cytoplasm of cancer cells (Figure 1A). A
positive p-MET 1234/1235 was identified in 12 patients
(7%). A positive p-MET 1234/1235 was found more fre-
quently in the tumors with positive expression of HGF (p 
0. 012). No significant association of p-MET 1234/1235 was
identified with the clinical factors and the amplification of
MET (Table 1).
Analysis of MET Gene Amplification and IHC
Analysis of HGF
MET amplification was identified only in eight patients
(4%). No significant association of MET amplification was
identified with the clinical factors and HGF expression. HGF
staining was found mainly in the cytoplasm of cancer cells
(Figure 1C). Positive HGF expression was identified in 104
patients (57%). No significant association of HGF expression
was identified with the clinical factors (Table 1).
Prognosis of Patient According to the
Molecular Parameters
The detectable relative risk is estimated 2.0 with 90%
statistical power. A univariate analysis showed that old age,
pathologic N status, negative p-MET 1234/1235, and positive
expression of HGF were associated with an unfavorable
prognosis (Table 2). A multivariate analysis demonstrated
three variables (wild type of K-ras, negative p-MET 1234/
1235, and positive expression of HGF) independently asso-
ciated with the poor survival of patients (Table 3).
DISCUSSION
An EGFR mutation was found limitedly to the tumors
with wild type of K-ras and without amplification of MET.
EGFR mutations, K-ras mutations, and MET amplification
were all mutually exclusive. The MET amplification was
observed in eight patients with wild-type EGFR and wild-
type K-ras. These results are consistent with recent find-
FIGURE 1. Representative immunohistochemical (IHC)
staining. A, Positive expression of the p-MET 1234/1235
with brown stained membranes and cytoplasm is shown
(original magnification 400) the intensity score (IS) and
proportional score (PS) were judged as 3 and 2, respectively.
Therefore, IHC of tumor assumed a weak expression of 5. B,
Negative expression of the tyrosine 1234/1235 phosphoryla-
tion of MET (p-MET 1234/1235) is shown (original magnifi-
cation 400). C, Positive expression of the hepatocyte
growth factor (HGF) with brown stained cytoplasm is shown
(original magnification 400), the IS and PS were judged on
2 and 3, respectively. Therefore, IHC of tumor assumed a
weak expression of 5. D, Negative expression of the HGF is
shown (original magnification 400).
TABLE 2. Univariate Analysis Using a Proportional Hazard
Model for the Survival of 183 Patients with Lung Cancer
Variables Category
Univariate Analysis
95% Confidence
Interval Hazard Ratio p
Gender Male 0.880–11.582 1.181 0.269
Female 1
Age (yr) 69 1.001–1.808 1.345 0.049
69 1
pT T2–4 0.978–1.848 1.344 0.068
T1 1
pN Positive 1.041–2.273 1.538 0.031
Negative 1
EGFR mutation Positive 0.559–1.031 0.758 0.071
Negative 1
K-ras mutation Positive 0.553–1.515 0.915 0.730
Negative 1
p-MET Positive 0.236–0.826 0.441 0.011
Negative 1
MET amplification Positive 0.461–1.942 0.947 0.881
Negative 1
HGF expression Positive 1.004–1.828 1.355 0.047
Negative 1
EGFR, epidermal growth factor receptor; p-MET, tyrosine 1234/1235 phosphory-
lation of MET; HGF, hepatocyte growth factor.
TABLE 3. Multivariate Analyses of Various Prognostic
Factors
Variables
Characteristics
Risk
Ratio 95% CI pUnfavorable Favorable
Gender Male Female 1.201 0.880–1.642 0.248
Age (yr) 69 69 1.244 0.910–1.700 0.172
T status 2–4 1 1.161 0.834–1.618 0.376
N status Positive Negative 1.508 0.976–2.336 0.065
EGFR mutation Negative Positive 1.316 0.942–1.840 0.107
K-ras mutation Negative Positive 1.737 1.004–3.004 0.048
p-MET Negative Positive 2.865 1.484–5.525 0.002
MET amplification Negative Positive 2.004 0.851–4.717 0.112
HGF expression Positive Negative 1.506 1.095–2.070 0.012
95% CI, 95% confidence interval; EGFR, epidermal growth factor receptor;
p-MET, tyrosine 1234/1235 phosphorylation of MET; HGF, hepatocyte growth factor.
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ings.22–23 Onozato et al.23 reported MET gene amplification
mutually exclusive against mutation of EGFR, K-ras, and
HER2. These findings suggest that distinct mechanisms may
occur independently in tumors with EGFR, K-ras, and MET
alterations during the process of development of lung adeno-
carcinoma (Figure 2).
The prevalence of positive p-MET 1234/1235, which is
crucial in kinase activation,24 was observed in 7% (12/183) of
the tumors in this study. Nakamura et al.25 reported that a
tyrosine 1235 phosphorylation of MET using antityrosine
1235 phosphorylation Ab was positive in 22% (28 among 130
cases) of surgically resected Japanese lung adenocarcinoma.
This discrepancy could be related to the difference of anti-
body, position of tyrosine-phosphorylation, and method used
for IHC. Furthermore, tumors with positive p-MET 1234/
1235 were found significantly more frequently in the tumors
with positive expression of HGF (p 0.012). The correlation
between phosphorylation of MET and HGF expression sup-
ports the hypothesis that the HGF/MET loop may be acti-
vated in an autocrine fashion in cancer cells.13 Negative
p-MET 1234/1235 was significantly associated with poor
survival in this study. These data seem to be inconsistent with
those findings suggested that HGF/MET signaling is involved
in cancer invasion.26 However, Stella et al.27 reported that
activation of the Notch receptor resulted in transcriptional
down-regulation of MET and impairment of HGF-dependent.
In turn, MET activation leads to transcriptional induction of
the Notch signaling indicating that MET is able to self-tune
its own protein levels and the ensuring biochemical and
biologic outputs through stimulating invasive growth of the
Notch pathway. Nakamura et al.25 reported that the tyrosine
1235 phosphorylation of MET had no influence on survival.
Therefore, at present, the prognostic impact of tyrosine phos-
phorylation remains controversial, unless our results indi-
cated the poor prognosis in patients with negative p-MET
1234/1235. On the other hand, over expression of HGF was
significantly associated with poor survival, consistent with
the results of previous studies.28–30
The amplification of MET was identified in only 8 of
183 patients (4%). This low rate of MET amplification is
consistent with two recent findings,23,31 which showed MET
amplification in 5.6% (12 of 213) and 1.4% (2 of 148) in
Japanese NSCLC. MET amplification was not associated
with the clinical parameters, which is consistent with previ-
ous findings.21
Mutation of EGFR, mutation of K-ras, and amplifica-
tion of MET seem to be mutually exclusive event in lung
adenocarcinoma in this study (Figure 2). Both of EGFR
mutations and MET amplification did not affect survival of
patients in this study, which is consistent with the previous
study.32 The wild type of K-ras was associated with a poor
survival (p  0.048) in this study. In contrast, some reports
have demonstrated that K-ras mutation may be associated
with poor survival in NSCLC in white33 and Japanese pop-
ulations.34,35 However, Graziano et al.36 reported that K-ras
mutation has a statistically significant correlation with poor
survival only for the subgroup with stage II not with stage I
NSCLC. Moreover, a recent study also showed that K-ras
gene mutations are not independently associated with the
poor prognosis for Japanese lung adenocarcinoma patients in
whom 62% at stage I.32 Therefore, the prognostic impact of
K-ras gene mutation in lung adenocarcinoma remains con-
troversial. These divergent results might be due to the differ-
ence of race, mutation frequency, stage of the disease, and
statistical power related to number of patients examined.
The crosstalk between MET and EGFR, including the
Akt or K-ras pathways, has been implicated in each signal-
ing.37 In the near future, molecularly targeted agent, such as
EGFR-TKI for tumors with EGFR mutations, anti-EGFR
monoclonal antibody (cetuximab) for lung adenocarcinomas
without K-ras mutations, and MET inhibitor for those with
MET amplification, and anti-HGF monoclonal antibody for
those with HGF over expression, may bring benefits to
decrease mortality and morbidity.38,39
In conclusion, these results indicate that the EGFR,
K-ras mutation, and MET amplification are mutually exclu-
sive suggesting presence of several distinct mechanisms in
the development of lung adenocarcinoma. The wild type of
K-ras, negative p-MET 1234/1235, and overexpression of
HGF may therefore be useful markers for predicting poor
prognosis in patients with resectable lung adenocarcinoma.
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